NASDAQ:ZYME

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

Retrieved on: 
Thursday, May 2, 2024
CFO, LLP, Prior, News, Interim management, Pomerantz, SVP, Senior, Interim, Zymeworks

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME 

Retrieved on: 
Wednesday, April 24, 2024
CFO, LLP, Prior, News, Interim management, Pomerantz, SVP, Senior, Interim, Zymeworks

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME 

Retrieved on: 
Tuesday, April 16, 2024
CFO, LLP, Prior, News, Interim management, Pomerantz, SVP, Senior, Interim, Zymeworks

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

Retrieved on: 
Monday, April 8, 2024
Prior, CFO, SVP, Zymeworks, News, LLP, Senior, Interim management, Pomerantz, Interim

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

ZYMEWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Zymeworks Inc. on Behalf of Zymeworks Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 4, 2024
Interim management, Telephone, Senior, Interim, SVP, P.C, News, CFO

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME) on behalf of Zymeworks stockholders.

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME) on behalf of Zymeworks stockholders.
  • Our investigation concerns whether Zymeworks has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle (“Astle”) from the positions of Senior Vice President (“SVP”) and Chief Financial Officer (“CFO”), effective immediately.
  • On this news, Zymeworks’s stock price fell $0.64 per share, or 6.08%, to close at $9.88 per share on April 1, 2024.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)

Retrieved on: 
Tuesday, April 2, 2024
Interim management, Senior, Interim, SVP, Zymeworks, News, CFO, Private investigator

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ).

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ).
  • The investigation concerns whether Zymeworks and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, effective immediately.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

Retrieved on: 
Monday, April 1, 2024
CFO, SVP, Zymeworks, News, LLP, Senior, Interim management, Pomerantz, Interim

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Retrieved on: 
Saturday, June 3, 2023
Neoplasm, KOL, ICR, Progression-free survival, HER2, DOR, American Society of Clinical Oncology, RECIST, Research, Gallbladder cancer, PFS, IHC, ASCO, The Lancet, University, Annual general meeting, Corr, Kaplan–Meier estimator, In situ hybridization, Immunohistochemistry, Jazz Pharmaceuticals, BTC, Therapy, Society, ORR, Safety, Disease, Nursing, Medical imaging, Pharmaceutical industry, Patient

DUBLIN and VANCOUVER, BC, June 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.

Key Points: 
  • The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology .
  • The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
  • The KM estimated median PFS was 5.5 months [95% CI: 3.7, 7.2] with a range of 0.3 to 18.5 months.
  • Results of the pivotal HERIZON-BTC-01 trial (NCT04466891) indicate that the HER2-targeted, bispecific antibody zanidatamab demonstrates rapid, durable responses with a manageable safety profile in patients with treatment-refractory HER2-amplified BTC.

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Retrieved on: 
Friday, June 2, 2023
Neoplasm, KOL, ICR, Progression-free survival, HER2, DOR, American Society of Clinical Oncology, RECIST, Research, Gallbladder cancer, PFS, IHC, ASCO, The Lancet, University, Annual general meeting, Corr, Kaplan–Meier estimator, In situ hybridization, Immunohistochemistry, Jazz Pharmaceuticals, BTC, Therapy, Society, ORR, Safety, Disease, Nursing, Medical imaging, Pharmaceutical industry, Patient

DUBLIN and VANCOUVER, BC, June 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.

Key Points: 
  • The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology .
  • The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
  • The KM estimated median PFS was 5.5 months [95% CI: 3.7, 7.2] with a range of 0.3 to 18.5 months.
  • Results of the pivotal HERIZON-BTC-01 trial (NCT04466891) indicate that the HER2-targeted, bispecific antibody zanidatamab demonstrates rapid, durable responses with a manageable safety profile in patients with treatment-refractory HER2-amplified BTC.

Zymeworks To Host First Quarter 2023 Results Conference Call

Retrieved on: 
Monday, April 17, 2023
Biotechnology, General Health, Health, Inc., Pharmaceutical industry

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023.

Key Points: 
  • Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023.
  • Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2023 at 4:30 p.m. Eastern Time (ET).